The stock of Endo International plc – Ordinary Shares (NASDAQ:ENDP) is a huge mover today! About 4.94M shares traded hands. Endo International plc – Ordinary Shares (NASDAQ:ENDP) has declined 42.47% since April 8, 2016 and is downtrending. It has underperformed by 48.12% the S&P500.
The move comes after 5 months positive chart setup for the $3.63B company. It was reported on Nov, 10 by Barchart.com. We have $23.57 PT which if reached, will make NASDAQ:ENDP worth $1.27B more.
Endo International plc – Ordinary Shares (NASDAQ:ENDP) Ratings Coverage
Out of 16 analysts covering Endo International plc (NASDAQ:ENDP), 10 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 63% are positive. Endo International plc has been the topic of 36 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The rating was initiated by Barclays Capital with “Equal-Weight” on Thursday, January 21. The rating was maintained by Barclays Capital on Friday, May 6 with “Equal Weight”. The stock of Endo International plc – Ordinary Shares (NASDAQ:ENDP) earned “Outperform” rating by RBC Capital Markets on Wednesday, November 9. Deutsche Bank initiated Endo International plc – Ordinary Shares (NASDAQ:ENDP) on Tuesday, September 29 with “Buy” rating. Stifel Nicolaus maintained Endo International plc – Ordinary Shares (NASDAQ:ENDP) rating on Friday, May 6. Stifel Nicolaus has “Buy” rating and $75 price target. The stock has “Outperform” rating given by Leerink Swann on Tuesday, August 11. The firm earned “Underperform” rating on Friday, May 6 by Mizuho. As per Friday, May 6, the company rating was downgraded by RBC Capital Markets. Goldman Sachs initiated the stock with “Neutral” rating in Monday, June 6 report. The firm earned “Neutral” rating on Friday, May 6 by Piper Jaffray.
According to Zacks Investment Research, “Endo International plc is a global specialty healthcare company. It develops, manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel for pain, urology, endocrinology, and oncology. The company also provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and hypertension markets. Endo International plc, formerly known as Endo Pharmaceuticals Holdings Inc., is headquartered in Dublin, Ireland.”
Insitutional Activity: The institutional sentiment increased to 0.95 in Q2 2016. Its up 0.03, from 0.92 in 2016Q1. The ratio improved, as 76 funds sold all Endo International plc – Ordinary Shares shares owned while 90 reduced positions. 42 funds bought stakes while 115 increased positions. They now own 192.40 million shares or 1.49% more from 189.57 million shares in 2016Q1.
Putnam Investments Ltd accumulated 639,954 shares or 0.02% of the stock. Deutsche National Bank Ag owns 1.29 million shares or 0.01% of their US portfolio. Gateway Inv Advisers Ltd Liability Company has 0% invested in the company for 15,978 shares. Point72 Asset Management Lp accumulated 0.27% or 2.52M shares. Raymond James & Associate last reported 242,441 shares in the company. Clearbridge Invests Limited Liability Company last reported 0% of its portfolio in the stock. The California-based Los Angeles Capital Equity Rech has invested 0.06% in Endo International plc – Ordinary Shares (NASDAQ:ENDP). Blackrock Inv Mngmt Ltd Co holds 0.01% of its portfolio in Endo International plc – Ordinary Shares (NASDAQ:ENDP) for 453,651 shares. Gamble Jones Invest Counsel reported 14,575 shares or 0.02% of all its holdings. Sabby Mngmt Limited Liability Company owns 60,061 shares or 0.05% of their US portfolio. Synovus owns 980 shares or 0% of their US portfolio. Connor Clark And Lunn Mngmt Limited holds 661,964 shares or 0.08% of its portfolio. Creative Planning last reported 0% of its portfolio in the stock. Nomura Asset Management has invested 0.01% of its portfolio in Endo International plc – Ordinary Shares (NASDAQ:ENDP). Wealthtrust has invested 0% of its portfolio in Endo International plc – Ordinary Shares (NASDAQ:ENDP).
Another recent and important Endo International plc – Ordinary Shares (NASDAQ:ENDP) news was published by Valuewalk.com which published an article titled: “Endo International plc â€“ Ordinary Shares (ENDP) Collapses Taking Hedge Fund …” on May 06, 2016.
ENDP Company Profile
Endo International plc, incorporated on October 31, 2013, is a global specialty pharmaceutical firm focused on developing, manufacturing, marketing and distributing branded and generic pharmaceutical products, as well as over-the-counter medications through its operating companies- Endo Pharmaceuticals, Par Pharmaceutical, Paladin Labs and SOMAR. The Companyâ€™s divisions include U.S. Branded Pharmaceuticals, which offer portfolio of branded pharmaceuticals such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, BELBUCA, Fortesta Gel, Testim, Aveed, Supprelin LA, and XIAFLEX; U.S. Generic Pharmaceuticals portfolio consists of tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches, and International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American, South African and world markets. It sells generic products primarily in the United States across multiple therapeutic categories.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.